That cements their confidence in the success of the trials four sites actively recruiting for the MagSense® HER2 breast cancer study with multiple patients having completed the study. We now start 2022 having moved into a new facility that greatly expands our R&D capabilities and adds manufacturing capacity to support the commercial development of our nanoparticle products. Adding, “We feel the study is progressing in a positive direction and will provide material updates as they arise.”
IBX Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
